Anti-nausea: Zofran / Ondansetron

Generic Name: ondansetron

Zofran is an anti-nausea drug administered to many chemotherapy and radiation patients while they undergo treatment.

Nausea occurs when your body produces a signaling chemical called serotonin to induce nausea in response to treatment. This signal binds to a receptor in your body, which triggers the nausea. Zofran works by blocking the serotonin receptor, thus preventing the response.

Drug Administration

Zofran can be administered intravenously (IV) or orally in pill form. If taken as a pill, you should not double dose, even if you miss one pill. Take only as directed.

Side Effects

Most side effects are mild, but Zofran can impair your thinking and reaction time, so you shouldn’t drive while taking it. These side effects include blurred vision, anxiety, and fainting.

Other symptoms include a slowed heart rate, headaches, dry mouth, shivering, frequent urination, trouble breathing, and allergic reactions. Alert your doctor to any drug allergies you have.

For more information on Hodgkin's disease please see the following pages:

For more information on Non-Hodgkin Lymphoma, please see the following pages:

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap